CRISPR Gene Editing: The Invention That Rewrites DNA

Photo: Thirdman / Pexels
DNA sequences in living cells with letter-level accuracy.">CRISPR-Cas9 is a gene-editing technology derived from a bacterial immune system, adapted by Jennifer Doudna and Emmanuelle Charpentier into a programmable tool that can cut, modify, or replace specific sequences of DNA. Their landmark paper appeared in Science on June 28, 2012. CRISPR — Clustered Regularly Interspaced Short Palindromic Repeats — lets scientists edit any genome with a precision and ease that made previous gene-editing methods look like trying to correct a typo with a sledgehammer. The technology earned Doudna and Charpentier the 2020 Nobel Prize in Chemistry and, by 2023, had produced the first approved gene-editing therapy in human medicine.
The Bacterial Defense System Nobody Cared About
CRISPR sequences were first noticed in the genome of Escherichia coli by Japanese microbiologist Yoshizumi Ishino in 1987, published as an oddity in a paper on an unrelated topic. Nobody knew what they were. In 1993, Spanish microbiologist Francisco Mojica at the University of Alicante began studying these strange repeated sequences in salt-loving archaea and dedicated his career to understanding them. By 2003, Mojica had concluded, from careful analysis of the sequences between the repeats, that bacteria were storing fragments of viral DNA — keeping a molecular memory of past infections.
CRISPR — Clustered Regularly Interspaced Short Palindromic Repeats; short, repeated DNA sequences found in bacterial and archaeal genomes, originally identified as part of an adaptive immune system against viruses.
Mojica submitted his findings to four journals before Journal of Molecular Evolution accepted and published the paper in 2005. The paper proposed that CRISPR sequences constituted a bacterial adaptive immune system — a completely novel class of immunity not previously known to exist in bacteria. Reviewers at the other journals had rejected it as speculative. The idea that bacteria had adaptive immunity, a capability thought to be exclusive to vertebrates, was considered implausible.
Source: Mojica, F.J.M. et al. (2005). "Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements" — Journal of Molecular Evolution, Vol. 60, pp. 174–182. The foundational paper proposing CRISPR as an adaptive immune system.
By 2007, Rodolphe Barrangou and Philippe Horvath at the food company Danisco (working on yogurt bacterial cultures) confirmed the hypothesis experimentally: bacteria with CRISPR sequences were immune to the viruses whose DNA matched those sequences, and bacteria acquired resistance to new viruses by incorporating fragments of the new virus's DNA into their CRISPR arrays. This was published in Science in 2007.
The mechanism worked in three parts: first, bacteria captured fragments of viral DNA and inserted them into the CRISPR array as "spacers." Second, when the bacterium encountered the same virus again, it transcribed the CRISPR array into RNA. Third, this RNA, combined with Cas proteins (CRISPR-associated proteins), guided the Cas enzyme to the matching viral DNA and cut it — destroying the viral genome before it could replicate.
The key recognition was that Cas9, one of the Cas proteins, did the cutting, and that the guide RNA's sequence determined where it cut. Change the sequence of the guide RNA, and you could in principle direct Cas9 to cut any DNA sequence you chose.
How CRISPR-Cas9 Actually Works
The CRISPR-Cas9 system works in three components that together achieve programmable, precise DNA editing.
The guide RNA (gRNA) is a short piece of RNA — approximately 100 nucleotides long — that contains a 20-nucleotide sequence complementary to the target DNA site. RNA base-pairs with DNA by complementary matching: adenine pairs with uracil (in RNA), and guanine pairs with cytosine. The guide RNA acts like a search term in a database. Load it with the sequence for "exon 7 of the hemoglobin gene," and it will find that sequence in a genome of 3 billion base pairs with high specificity.
The Cas9 protein is an endonuclease — an enzyme that cuts DNA within a strand rather than at the ends. Cas9 is a large protein that holds the guide RNA and scans DNA until the guide RNA finds its complementary sequence. Cas9 then requires recognition of a short sequence called a PAM (Protospacer Adjacent Motif) — typically NGG — adjacent to the target. If both conditions are met, Cas9 makes a double-strand break: it cuts both strands of the DNA double helix at the same location.
The DNA repair machinery of the target cell does the rest. A double-strand break is one of the most serious forms of DNA damage a cell can sustain, and cells have two main repair pathways. NHEJ (Non-Homologous End Joining) rejoins the broken ends quickly but imprecisely, often introducing small insertions or deletions (indels) that disrupt the gene — useful for "knocking out" a gene. HDR (Homology-Directed Repair) uses a provided template to repair the break precisely, inserting the desired sequence — useful for correcting a mutation or inserting a new gene.
Source: Jinek, M., Chylinski, K., Fonfara, I., et al. (2012). "A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity" — Science, Vol. 337, pp. 816–821. The Doudna-Charpentier paper demonstrating programmable DNA cutting.
This is analogous to a search-and-cut function in a word processor, but operating on a document with 3 billion characters and running inside a living cell. The guide RNA is the search term. Cas9 is the cursor that travels to that location. The cut is the edit. The cell's repair machinery is the autocorrect that either roughly patches the cut (NHEJ) or precisely inserts replacement text using a provided template (HDR).
The programmability is what distinguishes CRISPR from previous gene-editing tools. Earlier methods — zinc finger nucleases and TALENs — could also cut DNA at specific locations, but designing them required engineering a new protein for each new target sequence, a months-long process costing tens of thousands of dollars. With CRISPR, targeting a new sequence requires synthesizing a 20-nucleotide guide RNA, a process that takes days and costs a few hundred dollars. This difference in accessibility transformed gene editing from a specialist tool into something available to molecular biology labs worldwide.
Doudna, Charpentier, and the 2012 Science Paper
Jennifer Doudna is a biochemist at the University of California, Berkeley, who had been studying RNA structure and function for two decades before CRISPR. Her entry into CRISPR research came in 2011 through a chance meeting with Emmanuelle Charpentier at a conference in Puerto Rico — they met informally and realized their complementary expertise could address the mechanism of the Cas9 system.
Charpentier, a French microbiologist then at Umeå University in Sweden, had been studying a small RNA called tracrRNA that was essential for Cas9 function but whose role was unclear. Doudna's lab had the structural and biochemical expertise to characterize the molecular mechanism.
Their collaboration produced a crucial simplification. The natural CRISPR system used two separate RNA molecules — the crRNA (carrying the targeting sequence) and the tracrRNA (required for Cas9 function). Doudna and Charpentier combined these into a single chimeric guide RNA (sgRNA), making the system easier to deploy in any organism. They also demonstrated that the guide sequence could be changed to retarget Cas9 to different DNA sequences — proving programmability.
The paper, published in Science on June 28, 2012, reported that the purified system could cut any DNA sequence specified by the guide RNA, both in test-tube reactions and in cell-free extracts. The conclusion was explicit: this system could be programmed to edit genomes.
Source: Jinek et al. (2012), Science, Vol. 337 — as above. Doudna has described the period immediately after submission as waiting anxiously to see if anyone recognized the implications.
Feng Zhang and the Race to Eukaryotic Cells
The 2012 Doudna-Charpentier paper demonstrated CRISPR-Cas9 editing in biochemical systems — purified proteins and DNA in test tubes. The next challenge was adapting it to work inside eukaryotic cells — cells with nuclei, like those of plants, animals, and humans. Prokaryotic bacteria have no nuclear membrane; their DNA is accessible. Eukaryotic cells sequester their DNA inside a nucleus, and their DNA is packaged around histone proteins into chromatin, creating a more complex target.
Feng Zhang, a Chinese-American biochemist at the Broad Institute of MIT and Harvard, had been working independently on gene editing tools and recognized the potential of CRISPR from reading an earlier 2011 paper on the bacterial system. His group worked in parallel with Doudna's through 2012, adapting Cas9 to function in human and mouse cells — adding nuclear localization signals to get the protein into the nucleus and optimizing the guide RNA for eukaryotic conditions.
Zhang's paper demonstrating CRISPR editing in human cells was published in Science on January 3, 2013, approximately six months after the Doudna-Charpentier paper. A paper from the laboratory of George Church at Harvard, demonstrating editing in human cells via a different Cas9 optimization approach, appeared on the same day in the same journal.
Source: Cong, L., Ran, F.A., Cox, D., et al. (2013). "Multiplex Genome Engineering Using CRISPR/Cas Systems" — Science, Vol. 339, pp. 819–823. Zhang's paper demonstrating CRISPR editing in human cells.
The six months between the two papers created the central question of the CRISPR patent dispute: was the application to eukaryotic cells obvious from the 2012 paper, or was it a separate invention?
The Patent Dispute: A Decade of Litigation
The CRISPR patent dispute is the most consequential intellectual property battle in the history of biotechnology. It began in 2012 when both the University of California (representing Doudna and Charpentier's group) and the Broad Institute (representing Zhang) filed patents on CRISPR-Cas9.
The Broad Institute requested and received expedited review through the patent interference process. In 2017, the Patent Trial and Appeal Board (PTAB) ruled that the Broad's claims — specifically for CRISPR in eukaryotic cells — did not interfere with the UC's claims for CRISPR in any cellular environment, because the eukaryotic application was a separate, non-obvious invention. The Broad's patents were upheld. UC appealed.
In 2022, the US Court of Appeals for the Federal Circuit ruled in the Broad's favor again, finding that the Broad's evidence showed they had reduced CRISPR to practice in eukaryotic cells by October 5, 2012 — before the UC group had done so. The UC's broad claims for CRISPR in all cells, including eukaryotes, were rejected.
However, in 2025, a new development reopened the case. A US appeals court found fault with aspects of the PTAB's earlier reasoning and sent the case back to the Patent Trial and Appeal Board for reconsideration of specific claims. The dispute, now in its twelfth year, continues to determine which institutions and companies hold the core IP rights to a technology that underlies a multi-billion-dollar biotech industry.
The European Patent Office has taken a different position, granting key patents to both parties but giving the UC group broader rights than the US rulings have.
The commercial consequence is that Doudna's connection with Caribou Biosciences and Intellia Therapeutics, and Zhang's connection with Editas Medicine, operate under different patent positions in different jurisdictions — creating a complicated landscape for companies developing CRISPR therapeutics.
Source: Chemistry World (2025). "CRISPR Nobel laureates get another chance to claim ownership in long-running patent dispute" — reporting on the 2025 court ruling sending the case back to PTAB.
The 2020 Nobel and the Unrecognized
The Nobel Prize in Chemistry 2020 was awarded to Jennifer Doudna and Emmanuelle Charpentier "for the development of a method for genome editing." It was the first Nobel in Chemistry awarded to two women exclusively, and only the seventh time a Nobel in Chemistry went to all women.
The prize generated its own controversy — not about whether the science deserved recognition, but about who had been left out. Feng Zhang's work adapting CRISPR to human cells was arguably as important commercially and medically as the foundational biochemistry, yet he was not recognized. Rodolphe Barrangou and Philippe Horvath, who confirmed the bacterial immune function of CRISPR experimentally in 2007, received no prize. Francisco Mojica, who dedicated his career to understanding CRISPR's biological function and whose 2005 paper was rejected by four journals, received no prize. The "three-person rule" of Nobel Prizes, combined with the committee's focus on the programming insight rather than the foundational biology, produced an award that many scientists felt was incomplete.
Source: The Conversation (2020). "Nobel Prize for CRISPR honors two great scientists — and leaves out many others" — analysis of the prize omissions by researchers familiar with the field's history.
| Year | Milestone | Actor |
|---|---|---|
| 1987 | CRISPR repeats first noticed in E. coli | Ishino, Japan |
| 1993 | Systematic study of CRISPR sequences begins | Mojica, Spain |
| 2005 | CRISPR proposed as adaptive bacterial immune system | Mojica et al. |
| 2007 | CRISPR immune function confirmed experimentally | Barrangou, Horvath (Danisco) |
| 2011 | Charpentier publishes tracrRNA role; meets Doudna | Charpentier, Umeå University |
| Jun 2012 | Doudna-Charpentier paper: programmable DNA cutting | Science, UC Berkeley / Umeå |
| Jan 2013 | CRISPR demonstrated in human and mouse cells | Zhang, Broad Institute; Church, Harvard |
| 2017 | PTAB rules Broad's eukaryotic patent valid | USPTO PTAB |
| 2018 | He Jiankui announces CRISPR-edited babies | Shenzhen, China |
| 2020 | Nobel Prize in Chemistry awarded | Doudna, Charpentier |
| Dec 2023 | FDA approves Casgevy, first CRISPR therapy | Vertex / CRISPR Therapeutics |
| 2025 | Patent case reopened at PTAB | US Court of Appeals |
CRISPR's journey from unnoticed bacterial sequences to approved human therapy spans almost 40 years, most of it outside the spotlight.
The He Jiankui Scandal: When CRISPR Crossed a Line
In November 2018, a Chinese biophysicist named He Jiankui stunned the scientific world by announcing at an international conference in Hong Kong that he had created the first human genetically edited babies. He had used CRISPR to disable the CCR5 gene in embryos before implantation, intending to confer resistance to HIV infection. Twin girls — named pseudonymously Lulu and Nana — had been born from the edited embryos. A third pregnancy from the experiment was reportedly underway.
The reaction from the scientific community was immediate and nearly uniformly condemnatory. The experiment violated established principles of research ethics in multiple ways: the medical need was not established (the parents could have protected against HIV infection through standard methods), the risks were poorly characterized, the consent process was inadequate, and germline editing — changes that would be inherited by future generations — was widely considered off-limits pending much more research. He had submitted forged ethics documents and deceived the medical team that implanted the embryos.
Source: Science (2019). "Chinese scientist who produced genetically altered babies sentenced to 3 years in jail" — AAAS coverage of the criminal conviction and its details.
A Shenzhen court found He guilty of illegal practice of medicine in December 2019. He was sentenced to three years in prison and fined CN¥3 million (approximately US$434,000). His two collaborators received shorter sentences. The Lulu and Nana case is not a cautionary tale about the potential of CRISPR but about the absence of international governance mechanisms sufficient to prevent a single rogue researcher from making irreversible edits to the human germline.
The scientific community's response has been to accelerate work on governance frameworks. The International Commission on the Clinical Use of Human Germline Genome Editing, co-sponsored by the US National Academies and the UK Royal Society, published a report in 2020 concluding that germline editing for reproduction is currently irresponsible and should not proceed — but not that it should never proceed, leaving the door open for future application under appropriate oversight.
The First Approved CRISPR Therapy: Casgevy
On December 8, 2023, the US FDA approved Casgevy (exagamglogene autotemcel), a CRISPR-based therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics, for the treatment of sickle cell disease in patients 12 years and older. It became the first CRISPR-based medicine approved for human use anywhere in the world. The UK had approved it one week earlier, on November 16, 2023.
Sickle cell disease is caused by a point mutation in the hemoglobin gene that causes red blood cells to form a rigid sickle shape, blocking blood vessels and causing recurring episodes of severe pain (vaso-occlusive crises), organ damage, and shortened lifespan. Approximately 100,000 Americans live with the disease, the vast majority of whom are Black.
Casgevy works by editing a patient's own hematopoietic stem cells — the blood-forming cells extracted from bone marrow. CRISPR is used to reactivate the fetal hemoglobin gene (BCL11A), which produces a form of hemoglobin that works normally and is naturally silenced after birth. By disrupting the BCL11A gene, the therapy causes the cells to continue producing fetal hemoglobin, which compensates for the defective adult hemoglobin.
In clinical trials, 29 of 29 patients with sickle cell disease who received Casgevy and were followed for at least 12 months experienced no severe vaso-occlusive crises during that period — compared to a pre-treatment rate of several episodes per year for most patients.
Source: STAT News (2023). "In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease" — reporting on the December 8, 2023 approval.
Casgevy's price was set at $2.2 million per patient — making it one of the most expensive therapies in history, though proponents argue that a one-time cure compares favorably with decades of ongoing treatment costs. Access for patients in lower-income countries, where sickle cell disease is most prevalent, remains an unresolved challenge.
Off-Target Effects and the Science of Safety
The enthusiasm for CRISPR has always been tempered by the question of off-target editing — whether Cas9 sometimes cuts DNA at locations other than the intended target. A 20-nucleotide guide RNA should be highly specific, but a genome of 3 billion base pairs contains many near-matches, and Cas9 can tolerate some mismatches.
Early studies found detectable off-target cutting in various contexts, raising concerns about unintended mutations, particularly in cancer-relevant genes. Subsequent research has largely validated CRISPR's specificity for therapeutic applications — clinical-grade guide RNAs are tested extensively for off-target activity before use — but has also produced improved variants designed to reduce the problem.
High-fidelity Cas9 variants (eCas9, HiFiCas9) have engineered mutations that reduce Cas9's tolerance for mismatches, making off-target cutting less likely at the cost of some efficiency. Base editing, developed by David Liu at Harvard, uses a chemically modified Cas9 that cannot cut DNA but can convert one DNA base to another (cytosine to thymine, or adenine to guanine) without making a double-strand break — eliminating one class of off-target risk. Prime editing, also from Liu's group, uses an even more refined approach that can make targeted insertions and substitutions without double-strand breaks or donor DNA templates.
The clinical safety record from Casgevy and the many CRISPR trials in progress is being built in real time. Long-term follow-up of patients will provide the population-level data needed to characterize rare off-target events.
Source: Innovative Genomics Institute (2024). "CRISPR Clinical Trials: A 2024 Update" — comprehensive survey of ongoing therapeutic trials and safety monitoring.
FAQs
Q: Who actually invented CRISPR gene editing?
A: The CRISPR immune system in bacteria was discovered by Francisco Mojica and described by multiple research groups from 1987 to 2007. Its adaptation as a programmable gene-editing tool was published by Jennifer Doudna and Emmanuelle Charpentier in June 2012, for which they won the 2020 Nobel Prize in Chemistry. Feng Zhang at the Broad Institute demonstrated the technology's application in human cells in January 2013 and holds key patents for that application.
Q: What does CRISPR actually stand for?
A: Clustered Regularly Interspaced Short Palindromic Repeats. The name describes the structure of the bacterial DNA sequences — short palindromic repeats arranged at regular intervals, with non-repeating sequences (spacers) between them. The "Cas" in CRISPR-Cas9 stands for CRISPR-associated, referring to the proteins encoded near the CRISPR arrays.
Q: Can CRISPR edit any gene?
A: In principle, yes — provided a suitable PAM sequence is near the target. In practice, efficiency varies by target location and cell type, some genes are harder to edit because of chromatin structure, and delivery into certain tissues (liver is easy; brain is hard) remains challenging. Researchers are actively developing delivery methods (including lipid nanoparticles and viral vectors) and Cas variants with different PAM requirements to expand the range of editable targets.
Q: Is CRISPR editing of human embryos legal?
A: In most countries, editing human embryos for reproductive purposes is either explicitly prohibited or operates under a moratorium. The He Jiankui case, in which edited embryos were implanted and babies were born, was treated as a criminal offense in China. Most regulatory authorities distinguish between somatic editing (editing non-reproductive cells in a living patient, which is legal with regulatory approval) and germline editing (editing embryos or reproductive cells in ways that affect future generations, which is generally prohibited or heavily restricted).
Q: What diseases could CRISPR treat?
A: Casgevy is approved for sickle cell disease and transfusion-dependent beta-thalassemia. Clinical trials are underway for various blood disorders, some cancers (engineered T-cell therapies), inherited blindness, and transthyretin amyloidosis (a heart and nerve disease). Longer-term targets include HIV (where CRISPR has been used to excise viral DNA from infected cells in animal models), muscular dystrophy, and a range of inherited genetic diseases. Cancer treatment via CRISPR-engineered immune cells (CAR-T) is an active and advancing therapeutic area.
Q: What was wrong with He Jiankui's experiment?
A: Multiple problems: the medical need was not established (standard HIV prevention methods existed), the consent process was inadequate and involved deception, the ethics review documents were forged, the risks of off-target editing in embryos were not adequately characterized, and the edits would be heritable — affecting any future children of the subjects without their consent. He was convicted of illegal medical practice and imprisoned. The scientific community's near-unanimous condemnation reflected both the ethical violations and the concern that premature germline editing would produce a backlash affecting legitimate therapeutic research.
Read next:
Follow new articles
Add SciHub101 to your feed reader to see new science and technology stories.
About the Author
SciHub101 is an independent science and technology publication founded and edited by Buğra Sözeri, a software engineer and app developer based in Türkiye. AI tools assist with drafting and research. Source documentation in the existing archive is uneven, and articles are being reviewed and corrected. The Editorial Team byline identifies editorial responsibility; it does not certify specialist or independent human review. Where we compare products, anything built by our own team is labelled as such — see the editorial guidelines and About page for how corrections and disclosures work.
Related Articles

The Invention of GPS
How Bradford Parkinson, Ivan Getting, and Roger Easton built a satellite navigation system for nuclear bombers that became the infrastructure of everyday life.

The IUD — A History of the Intrauterine Device From Silkworm Gut to Hormonal Revolution
From Richard Richter's 1909 silkworm-gut ring to the Dalkon Shield disaster and Mirena's hormonal breakthrough, the IUD's story spans medicine, law, and reproductive rights.

What Is CRISPR and How Does Gene Editing Actually Work?
Forget the headlines about designer babies for a minute. Here's what actually happens at the molecular level when Cas9 finds, unzips, and cuts a strand of DNA.

CRISPR Gene Editing: How It Works in 2026
From bacterial immune system to approved therapies: how CRISPR-Cas9, base editing, and prime editing are rewriting the genetic code of medicine.

The CRISPR Gene Editing Breakthrough
CRISPR turned a bacterial immune system into a gene-editing tool. This article explains the discovery, mechanism, clinical results, and ethical stakes.

CRISPR 3.0: The Gene-Editing Revolution That's Quietly Changing Medicine
In December 2023, the FDA approved Casgevy — the first CRISPR-based therapy for a human disease. It works in a single treatment session: a patient's stem cells are removed, their DNA edited, and the corrected cells returned. The results in sickle cell disease trials were striking. But Casgevy uses first-generation CRISPR, which cuts DNA like scissors. A newer class of tools — base editing and prime editing — can rewrite individual letters of the genetic code without cutting the double helix at all, dramatically reducing the risk of unintended edits. Clinical trials of these next-generation systems began in 2024. The field is not waiting for the conversation to catch up.